샘플 요청 목록

 카트 문의
시장보고서
상품코드
1571896

세계의 혈액 종양 검사 시장

Hemato Oncology Testing
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 92 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 혈액 종양 검사 시장은 2030년까지 미국에서 142억 달러에 달할 전망

2023년에 49억 달러로 추정되는 세계의 혈액 종양 검사 시장은 2030년에는 142억 달러에 달하며, 분석 기간인 2023-2030년 CAGR은 16.3%로 성장할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 혈액 종양 검사 서비스는 CAGR 15.4%를 기록하며, 분석 기간 종료시에는 86억 달러에 달할 것으로 예측됩니다. 혈액 종양 측정 키트 분야의 성장률은 분석 기간 중 CAGR 17.7%로 추정됩니다.

미국 시장은 13억 달러로 추정, 중국은 CAGR 20.7%로 성장 예측

미국의 혈액 종양 검사 시장은 2023년에 13억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 36억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년 CAGR은 20.7%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 11.5%와 13.7%로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.6%로 성장할 것으로 예측됩니다.

세계의 혈액 종양 검사 시장 - 주요 동향과 촉진요인 정리

혈액 종양 검사는 암 진단을 어떻게 바꾸는가?

백혈병, 림프종, 골수종 등 혈액암 진단에 특화된 혈액 종양 검사는 현대 암 진단의 핵심입니다. 이러한 검사에는 분자진단, 세포유전학, 세포유전학, 유세포 분석 등이 포함되며, 암세포, 유전자 변이 및 기타 바이오마커를 식별하여 조기 발견 및 표적 치료법 선택에 도움을 줍니다. 혈액암 발병률 증가와 맞춤형 의료의 부상으로 혈액 종양 검사에 대한 수요가 크게 증가하고 있습니다. 이 시장은 암 진단뿐만 아니라 질병 진행을 모니터링하고 치료 효과를 평가하는 데 필수적이며, 임상의에게 환자 관리에 대한 귀중한 인사이트을 제공합니다.

기술의 발전은 어떻게 혈액 종양 검사를 형성하고 있는가?

분자진단, 차세대 염기서열 분석(NGS) 및 액체생검 기술의 발전은 혈액 종양 검사에 혁명을 일으켰으며, NGS는 종합적인 유전체 프로파일링을 가능하게 하여 특정 치료법의 표적이 될 수 있는 돌연변이를 식별할 수 있도록 지원하여 정밀 종양학 분야를 발전시키고 있습니다. 혈류내 순환 종양 DNA를 분석하는 액체생검은 기존의 조직 생검을 대체할 수 있는 최소 침습적 대안을 제공하여 조기 진단과 암 진행을 지속적으로 모니터링할 수 있습니다. 데이터 분석에 AI와 바이오인포매틱스 툴의 통합은 검사 결과의 정확도를 더욱 높여 보다 신속하고 정확한 진단을 가능하게 합니다. 이러한 기술 혁신은 보다 개인화된 치료 계획의 길을 열어 혈액종양학 분야의 환자 치료 결과를 개선하고 있습니다.

부문과 용도는 혈액 종양 검사 시장을 어떻게 정의하고 있는가?

검사 유형에는 분자검사, 유세포 분석, 면역조직화학 등이 있으며, 특정 유전자 변이를 검출할 수 있는 분자검사가 가장 큰 점유율을 차지하고 있습니다. 중합효소연쇄반응(PCR), 차세대염기서열분석(NGS) 등의 치료기술이 시장을 주도하고 있으며, 암세포의 상세한 분석이 가능하여 맞춤 치료를 위한 중요한 정보를 제공합니다. 혈액 종양 검사의 용도에는 진단, 예후 예측, 치료 모니터링이 포함되지만, 조기 발견이 생존율 향상에 필수적이기 때문에 진단 검사가 가장 중요한 용도입니다. 시장을 주도하는 것은 병원, 진단 실험실 및 연구 기관이며, 병원은 첨단 검사 기술을 이용할 수 있으므로 가장 큰 최종사용자입니다.

혈액 종양 검사 시장의 성장을 가속하는 요인은 무엇인가?

혈액 종양 검사 시장의 성장은 혈액암 유병률 증가, 분자진단의 발전, 맞춤형 의료의 부상 등 여러 가지 요인에 기인합니다. 조기에 정확한 암 진단에 대한 수요가 증가하면서 분자 검사 및 NGS 기술이 광범위하게 도입되고 있습니다. 암 진단을 개선하기 위한 정부의 구상과 암 연구에 대한 자금 지원 증가도 시장 성장에 크게 기여하고 있습니다. 또한 표적치료제와 면역치료제의 개발로 인해 특정 바이오마커와 돌연변이를 식별하기 위한 고급 진단 검사에 대한 필요성이 증가하고 있습니다. 신흥 시장에서의 진단 역량 확대와 액체생검과 같은 최소침습적 검사법에 대한 관심이 높아지는 것도 시장 성장을 더욱 촉진하는 요인입니다.

조사 대상 기업의 예(주목 36사)

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Archerdx, Inc.
  • Arup Laboratories, Inc.
  • Asuragen, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffman-La Roche Ltd.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Molecularmd(Subsidiary of Icon PLC)
  • Qiagen N.V.
  • Sanofi SA
  • Thermo Fisher Scientific, Inc.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 24.10.31

Global Hemato Oncology Testing Market to Reach US$14.2 Billion by 2030

The global market for Hemato Oncology Testing estimated at US$4.9 Billion in the year 2023, is expected to reach US$14.2 Billion by 2030, growing at a CAGR of 16.3% over the analysis period 2023-2030. Hemato Oncology Testing Services, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$8.6 Billion by the end of the analysis period. Growth in the Hemato Oncology Assay Kits segment is estimated at 17.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 20.7% CAGR

The Hemato Oncology Testing market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 20.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.5% and 13.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Global Hemato Oncology Testing Market - Key Trends and Drivers Summarized

How Is Hemato Oncology Testing Transforming Cancer Diagnosis?

Hemato oncology testing, which focuses on diagnosing blood cancers such as leukemia, lymphoma, and myeloma, has become a cornerstone of modern cancer diagnostics. These tests include molecular diagnostics, cytogenetics, and flow cytometry to identify cancerous cells, genetic mutations, and other biomarkers that aid in early detection and targeted therapy selection. The increasing incidence of blood cancers, coupled with the rise in personalized medicine, has significantly driven demand for hemato oncology testing. This market is essential not only for diagnosing cancer but also for monitoring disease progression and assessing treatment efficacy, offering clinicians valuable insights into patient management.

How Are Technological Advancements Shaping Hemato Oncology Testing?

Technological advancements in molecular diagnostics, next-generation sequencing (NGS), and liquid biopsy techniques have revolutionized hemato oncology testing. NGS allows for comprehensive genomic profiling, helping identify mutations that may be targeted by specific therapies, thereby advancing the field of precision oncology. Liquid biopsies, which analyze circulating tumor DNA in the bloodstream, offer a minimally invasive alternative to traditional tissue biopsies, enabling earlier diagnosis and continuous monitoring of cancer progression. The integration of AI and bioinformatics tools in data analysis has further enhanced the accuracy of test results, allowing for quicker and more precise diagnoses. These innovations are paving the way for more personalized treatment plans, improving patient outcomes in hemato oncology.

How Are Segments and Applications Defining the Hemato Oncology Testing Market?

Test types include molecular tests, flow cytometry, and immunohistochemistry, with molecular tests holding the largest share due to their ability to detect specific genetic mutations. Technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) dominate the market, enabling detailed analysis of cancerous cells and providing crucial information for personalized treatment. Applications of hemato oncology testing include diagnosis, prognosis, and treatment monitoring, with diagnostic testing being the most significant application as early detection remains critical in improving survival rates. The market is driven by hospitals, diagnostic laboratories, and research institutions, with hospitals being the largest end-users due to their access to advanced testing technologies.

What Factors Are Driving the Growth in the Hemato Oncology Testing Market?

The growth in the hemato oncology testing market is driven by several factors, including the increasing prevalence of blood cancers, advancements in molecular diagnostics, and the rise of personalized medicine. The growing demand for early and accurate cancer detection has led to wider adoption of molecular tests and NGS technologies. Government initiatives aimed at improving cancer diagnostics, along with increased funding for cancer research, are also significant contributors to market growth. Furthermore, the development of targeted therapies and immunotherapies has heightened the need for advanced diagnostic tests to identify specific biomarkers and mutations. The expansion of diagnostic capabilities in emerging markets and the growing focus on minimally invasive testing methods, such as liquid biopsies, are additional drivers of market growth.

Select Competitors (Total 36 Featured) -

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Archerdx, Inc.
  • Arup Laboratories, Inc.
  • Asuragen, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffman-La Roche Ltd.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Molecularmd (Subsidiary of Icon PLC)
  • Qiagen N.V.
  • Sanofi SA
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Hemato Oncology Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Hematologic Cancers Drives Demand for Hemato Oncology Testing
    • Technological Advancements in Molecular Diagnostics Strengthen Growth of Hemato Oncology Testing Market
    • Increasing Focus on Personalized Medicine Expands Addressable Market for Precision Oncology Testing
    • Growing Adoption of Next-Generation Sequencing (NGS) in Hemato Oncology Testing Spurs Market Innovation
    • Rising Availability of Liquid Biopsy Solutions Generates Demand for Non-Invasive Cancer Testing
    • Expansion of Companion Diagnostics in Hemato Oncology Strengthens Business Case for Testing Solutions
    • Rising Focus on Early Cancer Detection and Screening Expands Hemato Oncology Testing Market
    • Growth in Targeted Cancer Therapies Drives Demand for Comprehensive Genetic Testing
    • Surge in Adoption of Immuno-Oncology Therapies Spurs Need for Advanced Testing Solutions
    • Rising Awareness and Accessibility of Cancer Testing in Emerging Markets Expands Market Opportunities
    • Growing Use of Artificial Intelligence and Machine Learning in Cancer Testing Accelerates Innovation
    • Regulatory Push for Precision Medicine in Oncology Strengthens Adoption of Hemato Oncology Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Hemato Oncology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Assay Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Assay Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Assay Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for IHC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for IHC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for IHC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for NGS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cytogenetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Hemato Oncology Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hodgkin Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hodgkin Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hodgkin Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • JAPAN
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • CHINA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • EUROPE
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Hemato Oncology Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • FRANCE
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • GERMANY
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Hemato Oncology Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • INDIA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Hemato Oncology Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Hemato Oncology Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • AFRICA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제